Google Next 2017

Google Next 2017 was held in San Francisco March 8-10. Over the 3 days, the company rolled out more than 100 announcements of products and services. In addition, several key customers such as SAP, Ebay, HSBC were profiled. Overall, more than 10,000 people attended the event which was a dramatic increase over last year.

One of the overarching themes of this year's event is the deeper integration of machine learning with Google Cloud. It was exciting to witness the pace of innovation and deep commitment Google is making towards becoming the AI company of choice for a number of different business verticals. TensorFlow, the new ML Engine, Firebase extensions and greater leverage of Google's massive network infrastructure where just a few of the highlights that are of keen interest to Neuveo. To date, over $30B has been invested in Google Cloud and network infrastructure.

Here we go!

jL

TensorFlow 1.0

TensorFlow 1.0 was announced on February 15, 2017 at the first annual TensorFlow Developer Summit. This is an important milestone for utilizing open source machine learning technology that will be optimized and scaled with broad adoption. TensorFlow and the Google Clould Platform together form the basis of neuveo's deep learning algorithms applied to quantitative ultrasound data and volumetric imaging. We're excited to be a part of the Google Cloud startup program and will be working with Google as we develop our application.

https://developers.googleblog.com/2017/02/announcing-tensorflow-10.html

The painful truth about cancer treatment

For all the progress we’ve made in identifying different types of cancer, the genomic profiles associated and the promise of targeted agents in fighting the diseases, the process for determining whether treatment is working or not remains painfully slow and subjective.  We can now better determine which therapy ‘should’ work based on individual genomic profiles, but we don’t know in advance of the treatment.  The clinical trials process for approving drugs and dosage is done in aggregate, reflecting an average or expected cause/effect response.  And for the growing number of targeted immunotherapies, the non-responder rate can be higher than traditional agents.  The result is a lot of uncertainty and stress.

Taking a snapshot using CT or PET scans after a course of treatment is our best way to answer the question – did the tumor shrink?  And oftentimes the answer is YES!!, only to get bad news that cancer is back in another 2-3 months.

What if you could use a low cost tumor camcorder creating many time-lapsed ‘pictures’ from the very beginning of treatment?   Of course, you can’t do that today because there is a limit to how much radiation the body can absorb.  But imagine having a safe, effective window inside the body that watches how the tumor changes every day.  Something that could tell you if a drug or radiation is working.  Maybe even allow your doctor to administer a lower dose with the same or better outcome?  Could you decrease painful side effects?  Would you sleep better knowing rather than waiting 2-3 months?

Neuveo is bringing this level of speed and certainty to validating if treatment is working.  And when it’s not, your doctor has the data to support trying something new.  There will continue to be breakthroughs in treatment.  New drugs, new molecules, new insights.  We want you to be able to pivot quickly because your treatment is personal and you are anything but average.